The FDA Objects to the Sale and Marketing of Nasal, Ophthalmic and Inhalable CBD Products

On December 22, the Food and Drug Administration (the “FDA”) issued new warning letters to five companies that illegally sold and marketed unapproved CBD products, which the companies claimed could prevent, diagnose, mitigate, treat or cure various medical conditions.

This latest round of enforcement actions was triggered by specific concerns with the manner in which many of these CBD products were administered, namely through nasal, ophthalmic and inhalation routes.

The five recipients of these warning letters are:

Bee Delightful, a Texas company, that claimed its “Canna Bees Rescue Blend,” a blend of honey and CBD, has the potential to reduce chronic pain, inflammation, depression and anxiety, to name a few. But what most likely triggered the FDA to target this company were claims that this blend of honey and CBD could help fight “the invisible enemies out there.” The FDA has repeatedly explained that it is focusing on companies selling fraudulent COVID-19 products, which it deems to be major threats to public health. G & L Wellness, LLC, a Wisconsin company, that sells and markets eye drops for pets and humans, which it both marketed as a “multi-symptom eye-care solution.” New Leaf Pharmaceuticals, LLC, a Connecticut company, that advertised CBD

Read More Here…

Share on facebook
Share on twitter
Share on reddit
Share on pinterest
Share on email

Bud Digest

Leave a Comment

Your email address will not be published. Required fields are marked *